Molecular Pathology, Staging, and Biomarkers in Adrenocortical Carcinoma: A Contemporary Clinical Review
Disease Biology and Molecular Pathology
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with an estimated incidence of 0.7–2 cases per million per year and a five-year overall survival of approximately 35%, a figure that reflects both late-stage presentation and the biological aggressiveness intrinsic to the disease 318. The current diagnostic standard—the WHO 5th edition classification—has replaced reliance on any single histopathological criterion with a multiparametric framework requiring evidence of malignancy from at least one validated scoring system (Weiss, Modified Weiss, Helsinki, or Reticulin algorithm), confirmation of adrenocortical origin, and assessment of proliferative markers including Ki-67 and mitotic figure counts 1. The Helsinki score, calculated as 3 × mitotic rate (>5/50 HPF) + 5 × necrosis + Ki-67 (hotspot), demonstrated sensitivity and specificity of 100% and 99.4%, respectively—superior to the classical Weiss criteria (100% sensitivity, 90.2% specificity)—and was independently prognostic in multivariate analysis (HR 1.027; 95% CI 1.005–1.049; p = 0.015) in a real-world Slovenian cohort 12.
At the molecular level, ACC is characterized by four major genotypic clusters: (i) Wnt/β-catenin signaling pathway alterations (CTNNB1 mutation, ZNRF3 deletion); (ii) p53/Rb1 cell cycle dysregulation (TP53, RB1, MDM2, CDK4, CDKN2A); (iii) chromosomal maintenance and chromatin remodeling (DAXX, ATRX, MEN1, TERT); and (iv) mismatch repair pathway deficiency (MLH1, MSH2, MSH6, PMS2) 1. Clusters (i) and (ii) predominate in high-grade tumors. IGF2 overexpression is a hallmark feature, and nuclear β-catenin translocation alongside aberrant p53 expression are frequently associated with poor prognosis 13. Epigenetic alterations further characterize the disease: hypermethylation of PAX5, GSTP1, PYCARD, PAX6, and G0S2 has been reported, with PAX5 methylation demonstrating independent prognostic association in multivariable survival analysis 1. These molecular findings collectively define ACC as a heterogeneous malignancy in which biological behavior is shaped by pathway-level dysregulation rather than single-gene alterations alone 1118.
ENSAT Staging: Prognostic Framework and Clinical Implications
The ENSAT staging system, developed by the European Network for the Study of Adrenal Tumors, is the internationally accepted standard for ACC prognostication, and is considered superior to the UICC TNM classification for outcome prediction 13. ENSAT stage integrates tumor size, local invasion, lymph node status, and distant metastasis to stratify patients into stages I–IV. Real-world data confirm its prognostic validity: in a 17-year Slovenian retrospective cohort of 48 patients, five-year disease-specific survival rates were 100%, 56%, 50%, and 0% for stages I, II, III, and IV, respectively, with ENSAT stage retaining independent prognostic value in multivariate analysis (HR 2.796; 95% CI 1.258–6.212; p = 0.012) 2.
The completeness of surgical resection (R-status) interacts critically with ENSAT stage. The Spanish multidisciplinary consensus reports five-year overall survival of approximately 64.8% following R0 (microscopically negative margin) resection compared with 33.8% for incomplete (R1/Rx) resection 3. This difference underscores that surgical quality is as determinative as stage in shaping long-term outcomes, and is directly relevant to adjuvant therapy planning—several studies indicate that mitotane benefit is most pronounced in patients achieving R0 resection (HR for OS 0.46; 95% CI 0.30–0.69; p < 0.001) 7.
Ki-67 Index: Thresholds, Clinical Role, and Limitations
Ki-67 labeling index is the most widely applied proliferative biomarker in ACC risk stratification and is incorporated into multiple clinical algorithms. Two thresholds are clinically operative: Ki-67 >10% defines high-proliferation tumors in the ADIUVO adjuvant mitotane trial context, while Ki-67 ≥20% is used as a high-grade indicator within the S-GRAS prognostic score 311. For diagnostic purposes, a 5% cut-off demonstrates excellent specificity (pooled 0.98; 95% CI 0.95–0.99) and moderate sensitivity (0.82; 95% CI 0.65–0.92) for identifying malignant adrenocortical tumors in a meta-analysis of 26 studies 9. High Ki-67 (>10%) has also been shown to be an effect modifier for mitotane response, with registry-based data from the ICARO-GETTHI/SEEN cohort demonstrating that high Ki-67 tumors derive more benefit from adjuvant mitotane 10.
Despite its utility, Ki-67 assessment carries important limitations. Interobserver and inter-laboratory variability is well-documented and incompletely characterized across centers. Differences in antibody selection, staining protocol, counting methodology (hotspot vs. whole-section), and observer experience all influence reported values 313. The Spanish consensus explicitly acknowledges this gap as requiring standardization. Consequently, Ki-67 should be interpreted in conjunction with ENSAT stage, Weiss/Helsinki score, and margin status rather than as an isolated determinant.
Somatic Mutation Profile and Molecular Subtypes
| Pathway / Gene | Alteration Type | Prognostic Relevance | Therapeutic Relevance |
|---|---|---|---|
| CTNNB1 / Wnt-β-catenin | Activating mutation | Moderate; distinct clinicopathologic features | Preclinical interest; no approved targeted therapy |
| TP53 / p53-Rb axis | Loss-of-function mutation | Poor prognosis; high-grade phenotype | No established ACC-specific targeted agent |
| ZNRF3 | Deletion (Wnt pathway) | Emerging; often co-occurs with CTNNB1 | Investigational |
| IGF2 | Frequent overexpression | Common molecular feature; prognostic | IGF1R inhibition largely ineffective clinically |
| DAXX / ATRX / MEN1 | Chromatin remodeling | Prognostic in subsets | Investigational |
| MLH1, MSH2, MSH6, PMS2 | Mismatch repair deficiency | Prognostic | Potential PD-1 inhibitor eligibility |
| PAX5 methylation (epigenetic) | Promoter hypermethylation | Independent OS association | Not yet actionable |
Notably, targeted therapies directed at these pathways have yielded modest results in clinical trials. mTOR inhibitors and tyrosine kinase inhibitors (TKIs) show favorable preclinical activity, and multi-kinase inhibitors (MKIs) in advanced ACC demonstrate a pooled objective response rate of 21% (95% CI 11–36%) and disease control rate of approximately 57% in a recent meta-analysis of 11 studies 19. Combination strategies pairing MKIs with immune checkpoint inhibitors may improve upon these figures, and cabozantinib or lenvatinib combinations show disease control rates ≥50% and progression-free survival exceeding 6 months in preliminary data 17. Molecular profiling therefore increasingly informs prognosis and trial eligibility, though actionable clinical translation remains incomplete 1113.
Predictive Biomarkers for Adjuvant Mitotane Response
A fundamental distinction must be maintained between prognostic markers (predicting outcome irrespective of treatment) and predictive biomarkers (identifying differential benefit from a specific therapy). Most currently available molecular data in ACC are prognostic; validated predictive biomarkers for mitotane response remain elusive 13.
Among the most promising candidates, CYP2W1 (an orphan cytochrome P450 enzyme) has shown association with mitotane benefit in a cohort of 72 mitotane-treated patients: higher CYP2W1 immunoreactivity was associated with longer overall survival (HR 3.9; p = 0.009) and longer time to progression (HR 4.9; p = 0.001) after adjustment for ENSAT stage and Ki-67 23. Mechanistically, CYP2W1 is hypothesized to bioactivate mitotane or related compounds into cytotoxic species within tumor cells; it is more highly expressed in hormonally active, differentiated tumors with lower Ki-67, suggesting an inverse relationship between proliferative grade and CYP2W1 expression 21. In a 2023 European Congress of Endocrinology study of 62 ACC patients, combined immunohistochemical evaluation of RRM1, CYP2W1, and SOAT1 (sterol-O-acyltransferase-1) showed improved disease-free survival in patients with low-to-moderate expression of all three markers compared to those with high expression (RRM1 P = 0.037; CYP2W1 P = 0.020; SOAT1 P = 0.001) 23. These findings are conceptually compelling but remain preliminary, limited by retrospective design, heterogeneous treatment protocols, and small sample sizes.
At the mechanistic level, mitotane activates the ATF4/ATF3 endoplasmic reticulum stress axis and suppresses steroidogenic genes including STAR, CYP11A1, CYP21A2, and HSD3B2 in a dose-dependent manner in H295R cells 14. A separate prognostic and predictive signal has emerged from GDF-15: mitotane treatment induces GDF-15 secretion in ACC cells, serum GDF-15 below the median is associated with longer survival, and in 46 patients receiving immune checkpoint inhibition, low GDF-15 correlated with both objective response (p = 0.0379) and longer progression-free survival (p = 0.036) 12. This finding has practical implications: mitotane-mediated GDF-15 induction may suppress pro-inflammatory immune gene expression and reduce tumor immune infiltration, potentially limiting the efficacy of sequential or concurrent immunotherapy.
From a pharmacokinetic perspective, total plasma mitotane levels measured within the first month of therapy are prognostically significant in metastatic ACC (p = 0.026 for first level; AUC p = 0.048), with a minimum effective threshold of 10–15 mg/L or AUC >100 mg/L/month identified prospectively 4. Importantly, free mitotane (unbound fraction) and lipoprotein-bound fractions added no independent prognostic value beyond total mitotane level, supporting total level monitoring as the practical clinical standard 4. Mitotane-associated adverse events are very common in adjuvant settings; in one series, all treated patients experienced at least one adverse event, with 34.6% experiencing more than six distinct adverse effects, underscoring the necessity of rigorous monitoring protocols 6. Pharmacovigilance analyses also identify potentially unlabeled toxicities including QT interval prolongation, amnesia, and ovarian cysts 16.
Clinical Integration and Unresolved Questions
A practical postoperative risk assessment framework should integrate: (1) ENSAT stage as the primary prognostic scaffold; (2) R-status (R0 vs. R1/Rx) as a treatment-modifying factor; (3) Ki-67 index for proliferative risk stratification; (4) Helsinki or Weiss score for histopathological confirmation; and (5) emerging molecular profiling for prognostic enrichment and trial eligibility 1117. Adjuvant mitotane is supported by meta-analytic evidence for improved recurrence-free survival (HR 0.63; 95% CI 0.44–0.92) and, particularly for R0-resected patients, improved overall survival 7. Registry data further suggest the benefit is most pronounced in males, younger patients, those with high Ki-67, and those with venous invasion, with effects diminishing after 24 months—consistent with a primarily cytostatic rather than curative mechanism 10. Adjuvant radiotherapy independently improves overall survival (HR 0.63; p = 0.007), with strongest benefit in ENSAT stage III disease 8.
Critical evidence gaps persist. CYP2W1, RRM1, and SOAT1 as predictive biomarkers require validation in large, prospective, adequately powered cohorts with standardized assay protocols and mitotane dosing. GDF-15's role in immunotherapy resistance is biologically coherent but awaits clinical validation. Interobserver variability in Ki-67 assessment and molecular subtyping remain incompletely resolved. No validated pharmacogenomic tool yet exists that reliably identifies individual patients who will achieve durable benefit from mitotane. Clinicians should regard current biomarker evidence as complementary to established staging and proliferation indices, pending rigorous prospective validation in international registries and randomized trials 111317.